Statements (160)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:robotics |
| gptkbp:administration_guidelines |
follow prescribing information
monitor for side effects ensure proper dosing |
| gptkbp:application |
gptkb:transportation
surveillance delivery |
| gptkbp:battery_life |
8 hours
|
| gptkbp:class |
analgesics
opioids |
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:Canada gptkb:United_States gptkb:National_Institutes_of_Health gptkb:Alder_Bio_Pharmaceuticals Phase 1 pharmaceutical companies Phase 2 Phase 3 private investors randomized controlled trial safety profile assessment double-blind study pain reduction placebo-controlled trial tolerability assessment |
| gptkbp:collaborations |
academic institutions
clinical research organizations |
| gptkbp:color |
gptkb:black
gptkb:white gray |
| gptkbp:contraindication |
severe asthma
respiratory disorders alcohol use hypersensitivity to oxycodone concurrent use of MAO inhibitors |
| gptkbp:control_system |
gptkb:manual
autonomous |
| gptkbp:country_of_origin |
gptkb:USA
|
| gptkbp:deployment |
rural areas
urban areas industrial sites |
| gptkbp:designed_by |
ARX Corporation
|
| gptkbp:developed_by |
gptkb:Alder_Bio_Pharmaceuticals
|
| gptkbp:development |
pharmaceutical companies
biotechnology firms |
| gptkbp:dosage_form |
spray
|
| gptkbp:effective_date |
not approved by FDA
|
| gptkbp:environment |
outdoor
indoor |
| gptkbp:feature |
gptkb:remote_control
GPS navigation real-time data processing automated charging |
| gptkbp:formulation |
intranasal
nalbuphine hydrochloride |
| gptkbp:funding |
gptkb:venture_capital
non-profit organizations government grants private funding private investors pharmaceutical company funding |
| gptkbp:future_prospects |
long-term effects
cost-effectiveness analysis patient-reported outcomes comparative efficacy studies |
| gptkbp:has_ability |
gptkb:navigation
obstacle avoidance |
| https://www.w3.org/2000/01/rdf-schema#label |
ARX-04
|
| gptkbp:indication |
chronic pain
acute pain post-operative pain pain from injury trauma-related pain |
| gptkbp:ingredients |
oxycodone
nalbuphine |
| gptkbp:intended_use |
acute pain relief
|
| gptkbp:invention |
patented
|
| gptkbp:investment |
acute pain management market
emergency medicine market post-operative pain market |
| gptkbp:is_effective_against |
under investigation
|
| gptkbp:maintenance |
6 months
|
| gptkbp:manufacturer |
gptkb:Alder_Bio_Pharmaceuticals
ARX Corporation |
| gptkbp:market |
gptkb:military
commercial |
| gptkbp:market_position |
investigational
not available in pharmacies |
| gptkbp:marketed_as |
gptkb:health_services
|
| gptkbp:max_speed |
60 km/h
|
| gptkbp:mechanism_of_action |
opioid receptor agonist
mu-opioid receptor agonist |
| gptkbp:operating_system |
gptkb:Linux
|
| gptkbp:part_of |
robotics industry
ARX fleet autonomous systems market |
| gptkbp:patient_population |
gptkb:children
adults elderly post-operative patients cancer patients patients with neuropathic pain |
| gptkbp:price |
gptkb:$100,000
|
| gptkbp:project |
clinical development
|
| gptkbp:protocol |
gptkb:Wi-Fi
gptkb:Bluetooth |
| gptkbp:regulatory_compliance |
gptkb:ISO_9001
gptkb:FCC gptkb:CE_Marking not yet approved |
| gptkbp:research |
pharmacokinetics
efficacy studies safety studies |
| gptkbp:research_focus |
pain management
opioid delivery systems |
| gptkbp:research_institutes |
gptkb:Mayo_Clinic
gptkb:Duke_University gptkb:Johns_Hopkins_University gptkb:University_of_California gptkb:Cleveland_Clinic |
| gptkbp:research_output |
enhanced patient satisfaction
improved pain scores reduced opioid consumption |
| gptkbp:route_of_administration |
nasal
intranasal delivery |
| gptkbp:safety_features |
fire suppression
under investigation collision detection emergency stop |
| gptkbp:safety_measures |
adverse event reporting
long-term follow-up |
| gptkbp:sensor |
gptkb:camera
LIDAR |
| gptkbp:service_frequency |
as needed
|
| gptkbp:side_effect |
dizziness
nausea constipation sedation respiratory depression |
| gptkbp:support |
24/7 customer service
software updates technical training |
| gptkbp:target_audience |
patients with acute pain
patients with severe pain |
| gptkbp:targets |
mu-opioid receptor
kappa-opioid receptor |
| gptkbp:type |
gptkb:vehicles
|
| gptkbp:used_for |
acute pain
severe pain management |
| gptkbp:user_interface |
gptkb:mobile_app
touchscreen voice control |
| gptkbp:uses_technology |
gptkb:machine_learning
gptkb:AI_technology |
| gptkbp:weight |
1500 kg
|
| gptkbp:year_established |
gptkb:2021
|
| gptkbp:bfsParent |
gptkb:Acel_Rx_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|